GalNAc‐siFABP5 treatment reduced serum AST, ALT, TC, TG levels (Figure 7e,f), attenuated hepatic steatosis and fibrosis progression, and lowered inflammation and NAS scores. This evidence concerns the gene GPT and Hepatic steatosis.